Raynaud's phenomenon Medical Services in China

Raynaud's phenomenon is a vasospastic disorder characterized by episodic, reversible constriction of the small arteries and arterioles supplying the fingers and toes—less commonly the nose, ears, lips, or nipples—in response to cold exposure or emotional stress. It manifests as sequential color changes: pallor (white) due to ischemia, followed by cyanosis (blue) from deoxygenated blood stasis, and finally rubor (red) upon reperfusion. Two main forms exist: primary Raynaud’s (idiopathic, benign, no underlying disease) and secondary Raynaud’s (associated with systemic rheumatic or autoimmune conditions such as systemic sclerosis, lupus, Sjögren’s syndrome, dermatomyositis, or mixed connective tissue disease). Pathophysiologically, it involves dysregulation of vascular tone mediated by sympathetic hyperreactivity, endothelial dysfunction (reduced nitric oxide bioavailability, elevated endothelin-1), abnormal smooth muscle responsiveness, and microvascular structural remodeling—particularly prominent in secondary cases. Genetic predisposition (e.g., polymorphisms in alpha-2 adrenergic receptors and endothelial nitric oxide synthase genes), hormonal influences (higher prevalence in women), and environmental triggers (cold, vibration, smoking, certain medications like beta-blockers or stimulants) contribute to susceptibility. Epidemiologically, primary Raynaud’s affects approximately 3–5% of the general population globally, with higher prevalence (up to 10–15%) in colder climates and among women aged 15–40 years. Secondary Raynaud’s occurs in up to 90% of patients with systemic sclerosis and is also common in early-stage lupus or inflammatory myopathies. Key risk factors include female sex, family history, living in cold regions, occupational vibration exposure (e.g., jackhammer use), smoking, and preexisting autoimmune disease as merely uncomfortable, Raynaud’s significantly impairs quality of life: patients report limitations in daily activities (e.g., handling refrigerated items, outdoor winter tasks), sleep disruption due to nocturnal attacks, anxiety about triggering environments, and social withdrawal. In severe secondary cases, chronic ischemia may lead to digital ulcers, pitting scars, gangrene, or even autoamputation—requiring multidisciplinary rheumatologic, dermatologic, and sometimes vascular surgical intervention. Early diagnosis and differentiation between primary and secondary forms are critical, as the latter demands comprehensive autoimmune screening (ANA, ENA, nailfold capillaroscopy, ESR/CRP) and proactive management to prevent end-organ damage.

Raynaud’s phenomenon (RP) is a vasospastic disorder characterized by episodic digital ischemia triggered by cold exposure or emotional stress, resulting in sequential color changes—pallor (white), cyanosis (blue), and rubor (red)—in the fingers and/or toes. It may occur as a primary (idiopathic) condition or secondary to underlying systemic rheumatic diseases such as systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, or inflammatory myopathies. Management in the Department of Rheumatology and Immunology focuses on symptom control, prevention of tissue damage, and identification/treatment of associated autoimmune conditions. A comprehensive, individualized approach integrates conservative strategies, pharmacotherapy, and, rarely, surgical intervention.

Conservative treatment forms the cornerstone of RP management and should be initiated at diagnosis. Patients are advised to avoid cold exposure through layered clothing, insulated gloves and socks, and use of hand warmers; ambient indoor temperatures should be maintained above 20°C. Smoking cessation is mandatory, as nicotine induces vasoconstriction and impairs endothelial function. Stress reduction techniques—including cognitive behavioral therapy, mindfulness-based stress reduction, and biofeedback—have demonstrated efficacy in reducing attack frequency and severity. Regular aerobic exercise improves peripheral circulation and autonomic regulation. Patients should avoid vasoconstrictive agents, including over-the-counter decongestants (e.g., pseudoephedrine), stimulants, and certain migraine medications (e.g., ergot derivatives). Digital protection is critical: patients must inspect hands and feet daily for ulceration or infection, wear well-fitting footwear, and avoid trauma. In cold climates, pre-warming vehicles and using heated steering wheel covers or seat warmers can mitigate triggers. Education regarding early recognition of digital ulcers—characterized by painful, punched-out lesions often at fingertip pulp or nail fold—is essential to prompt referral and prevent progression to gangrene.

Pharmacologic therapy is indicated for patients with frequent, disabling attacks, digital ulcers, or evidence of digital ischemia on capillaroscopy or nailfold videocapillaroscopy (NVC). First-line agents are calcium channel blockers (CCBs), particularly nifedipine extended-release (30–90 mg/day), which reduce attack frequency by ~50% and improve digital blood flow. Amlodipine and felodipine are alternatives for patients intolerant to nifedipine. For refractory cases, phosphodiesterase type 5 inhibitors (e.g., sildenafil 20 mg three times daily or tadalafil 10–20 mg once daily) demonstrate robust efficacy in improving digital perfusion and healing ulcers. Topical nitrates (e.g., 0.2% nitroglycerin ointment applied to ulcer margins) promote local vasodilation and accelerate ulcer healing but may cause headache or hypotension. Endothelin receptor antagonists—bosentan (62.5 mg twice daily, titrated to 125 mg twice daily)—are FDA-approved for digital ulcer prevention in systemic sclerosis-associated RP and significantly reduce new ulcer formation. Intravenous prostanoids (e.g., iloprost 0.5–2.0 ng/kg/min for 6 hours daily over 3–5 days) are reserved for severe, acute ischemia or active digital ulcers unresponsive to oral therapy; they induce potent vasodilation and inhibit platelet aggregation. Newer agents under investigation include Rho-kinase inhibitors (e.g., fasudil) and selective serotonin receptor antagonists (e.g., ketanserin), though these remain off-label in most jurisdictions. All pharmacotherapy requires careful monitoring for hypotension, edema, or drug interactions—especially with anticoagulants or antihypertensives.

Surgical treatment is exceedingly rare and reserved for end-stage complications. Digital sympathectomy—either open or minimally invasive (endoscopic thoracic or digital)—may be considered for unilateral, severe, refractory RP with recurrent ulcers or gangrene unresponsive to maximal medical therapy. However, evidence supporting long-term efficacy is limited, recurrence rates are high (up to 40% at 2 years), and risks include compensatory sweating, neuralgia, and incomplete relief. Botulinum toxin A (Botox) injections into the digital pulp or palm have emerged as a less invasive alternative, blocking sympathetic neurotransmission and demonstrating significant improvement in ulcer healing and pain reduction in small randomized trials; effects typically last 3–6 months and may be repeated. Surgical revascularization is not feasible due to the microvascular nature of RP pathology.

Treatment advantages in China reflect integrated clinical infrastructure, traditional medicine synergy, and rapid adoption of evidence-based innovations. Major tertiary hospitals—such as Peking Union Medical College Hospital, West China Hospital, and Shanghai Renji Hospital—house specialized Raynaud’s clinics with multidisciplinary teams (rheumatologists, vascular surgeons, dermatologists, rehabilitation specialists) and advanced diagnostic tools including high-resolution NVC, laser Doppler imaging, and thermography. China’s National Health Commission has incorporated RP management guidelines into the national rheumatic disease registry, enabling real-world data collection and quality benchmarking. Traditional Chinese Medicine (TCM) is frequently integrated: acupuncture at LI4 (Hegu), SP6 (Sanyinjiao), and BL17 (Geshu) demonstrates adjunctive benefits in improving microcirculation and reducing attack frequency in randomized controlled trials published in journals like *Chinese Medical Journal*. Standardized TCM formulas—such as Danggui Sini Tang (Tangkuei Four-Ingredient Decoction)—are prescribed under rheumatologist supervision for patients with cold-damp or blood-stasis patterns, with pharmacovigilance protocols ensuring herb–drug interaction screening. Moreover, China’s robust generic pharmaceutical industry ensures broad access to affordable nifedipine, sildenafil, and bosentan, while domestic biotech firms are advancing novel endothelin antagonists and prostacyclin analogs currently in Phase III trials.

Recovery and long-term management emphasize patient empowerment and structured follow-up. Patients should maintain a symptom diary tracking attack frequency, duration, triggers, and ulcer development. Annual rheumatologic evaluation includes assessment for evolving connective tissue disease via ANA, ENA, anti-Scl-70, anti-centromere, and high-resolution NVC. Capillaroscopic abnormalities—such as giant capillaries or avascular areas—are predictive of systemic sclerosis development and warrant intensified surveillance. Nutritional support includes omega-3 fatty acids (2–4 g/day) and antioxidants (vitamin C 500 mg/day, vitamin E 400 IU/day), shown in cohort studies to modestly improve endothelial function. Psychological resilience is fostered through hospital-based peer support groups and telehealth counseling services, now widely available via platforms like WeDoctor and Ping An Good Doctor. Finally, pregnancy counseling is essential for women of childbearing age, as RP often improves during gestation but requires careful medication review—CCBs and sildenafil are generally avoided in the first trimester, while topical nitrates may be used cautiously. With consistent adherence to conservative measures, timely pharmacotherapy, and vigilant monitoring, >85% of patients achieve meaningful symptom control and preserved digital integrity over 10-year follow-up.